ReviewJournal of clinical pathology2001
Neuroblastoma tumour genetics: clinical and biological aspects.
Review in Journal of clinical pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Integrative precision oncology in neuroblastoma: multi-omics biomarkers, molecular targets, and immunotherapeutic strategies.Frontiers in oncology · 2026Review
- Review
- Mutational topography reflects clinical neuroblastoma heterogeneity.Cell genomics · 2023Article
- Article
- Chromosome 1p status in neuroblastoma correlates with higher expression levels of miRNAs targeting neuronal differentiation pathway.In vitro cellular & developmental biology. Animal · 2023Article
- Bioinformatics analysis of recurrent deletion regions in neuroblastoma.Medical oncology (Northwood, London, England) · 2022Article
- Molecular Basis and Clinical Features of Neuroblastoma.JMA journal · 2021Review
- Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets.Frontiers in cell and developmental biology · 2021Review
- Retinoic acid induces differentiation in neuroblastoma via ROR1 by modulating retinoic acid response elements.Oncology reports · 2020Article
- Nervous system: Embryonal tumors: Neuroblastoma.Atlas of genetics and cytogenetics in oncology and haematology · 2020Article
- Neuroblastoma: Tumor Biology and Its Implications for Staging and Treatment.Children (Basel, Switzerland) · 2019Review
- MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.Cell death & disease · 2018Article
- Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors.Scientific reports · 2017Article
- The role of anaplastic lymphoma kinase in pediatric cancers.Cancer science · 2017Review
- Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells.Cell reports · 2016Article
- Concurrent Presentation of Therapy Related Acute Myeloid Leukemia in a Case of Neuroblastoma.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016Article
- The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Implications of the Incidental Finding of a MYCN Amplified Adrenal Tumor: A Case Report and Update of a Pediatric Disease Diagnosed in Adults.Case reports in oncological medicine · 2013Article
- PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.International journal of cancer · 2012Article
- Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells.Pediatric surgery international · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma tumour cells show complex combinations of acquired genetic aberrations, including ploidy changes, deletions of chromosome arms 1p and 11q, amplification of the MYCN oncogene, and-most frequently-gains of chromosome arm 17q. Despite intensive investigation, the fundamental role of these features in neuroblastoma initiation and progression remains to be understood. Nonetheless, great progress has been made in relating tumour genetic abnormalities to tumour behaviour and to clinical outcome; indeed, neuroblastoma provides a paradigm for the clinical importance of tumour genetic abnormalities. Knowledge of MYCN status is increasingly being used in treatment decisions for individual children, and the clinical value of 1p and 17q data as adjuncts or refinements in risk stratification is under active investigation. Reliable detection of these molecular cytogenetic features should be regarded as mandatory for all new cases at presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.